REC602-HPV Bivalent (Type 6/11) Vaccine

We are also developing REC602, a bivalent HPV vaccine candidate targeting HPV 6/11, which is currently performing data evaluation and analysis on the phase I trial in China. We have completed the phase I trial in 2022. REC602 adopts a similar MoA with the recombinant HPV 9-valent vaccine.